The value of tailoring vial sizes to populations and locations.
Measles-rubella
Supply chain logistics
Tailoring
Vial size
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
21 01 2019
21 01 2019
Historique:
received:
14
09
2018
revised:
19
11
2018
accepted:
04
12
2018
pubmed:
24
12
2018
medline:
20
2
2020
entrez:
23
12
2018
Statut:
ppublish
Résumé
Frequently, a country will procure a single vaccine vial size, but the question remains whether tailoring the use of different size vaccine vial presentations based on populations or location characteristics within a single country could provide additional benefits, such as reducing open vial wastage (OVW) or reducing missed vaccination opportunities. Using the Highly Extensible Resource for Modeling Supply Chains (HERMES) software, we built a simulation model of the Zambia routine vaccine supply chain. At baseline, we distributed 10-dose Measles-Rubella (MR) vials to all locations, and then distributed 5-dose and 1-dose MR vials to (1) all locations, (2) rural districts, (3) rural health facilities, (4) outreach sites, and (5) locations with average MR session sizes <5 and <10 children. We ran sensitivity on each scenario using MR vial opening thresholds of 0% and 50%, i.e. a healthcare worker opens an MR vaccine for any number of children (0%) or if at least half will be used (50%). Replacing 10-dose MR with 5-dose MR vials everywhere led to the largest reduction in MR OVW, saving 573,892 doses (103,161 doses with the 50% vial opening threshold) and improving MR availability by 1% (9%). This scenario, however, increased cold chain utilization and led to a 1% decrease in availability of other vaccines. Tailoring 5-dose MR vials to rural health facilities or based on average session size reduced cold transport constraints, increased total vaccine availability (+1%) and reduced total cost per dose administered (-$0.01) compared to baseline. In Zambia, tailoring 5-dose MR vials to rural health facilities or by average session size results in the highest total vaccine availability compared to all other scenarios (regardless of OVT policy) by reducing open vial wastage without increasing cold chain utilization.
Sections du résumé
BACKGROUND
Frequently, a country will procure a single vaccine vial size, but the question remains whether tailoring the use of different size vaccine vial presentations based on populations or location characteristics within a single country could provide additional benefits, such as reducing open vial wastage (OVW) or reducing missed vaccination opportunities.
METHODS
Using the Highly Extensible Resource for Modeling Supply Chains (HERMES) software, we built a simulation model of the Zambia routine vaccine supply chain. At baseline, we distributed 10-dose Measles-Rubella (MR) vials to all locations, and then distributed 5-dose and 1-dose MR vials to (1) all locations, (2) rural districts, (3) rural health facilities, (4) outreach sites, and (5) locations with average MR session sizes <5 and <10 children. We ran sensitivity on each scenario using MR vial opening thresholds of 0% and 50%, i.e. a healthcare worker opens an MR vaccine for any number of children (0%) or if at least half will be used (50%).
RESULTS
Replacing 10-dose MR with 5-dose MR vials everywhere led to the largest reduction in MR OVW, saving 573,892 doses (103,161 doses with the 50% vial opening threshold) and improving MR availability by 1% (9%). This scenario, however, increased cold chain utilization and led to a 1% decrease in availability of other vaccines. Tailoring 5-dose MR vials to rural health facilities or based on average session size reduced cold transport constraints, increased total vaccine availability (+1%) and reduced total cost per dose administered (-$0.01) compared to baseline.
CONCLUSIONS
In Zambia, tailoring 5-dose MR vials to rural health facilities or by average session size results in the highest total vaccine availability compared to all other scenarios (regardless of OVT policy) by reducing open vial wastage without increasing cold chain utilization.
Identifiants
pubmed: 30578087
pii: S0264-410X(18)31655-4
doi: 10.1016/j.vaccine.2018.12.010
pmc: PMC6559229
mid: NIHMS1029741
pii:
doi:
Substances chimiques
Measles Vaccine
0
Rubella Vaccine
0
Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
637-644Subventions
Organisme : AHRQ HHS
ID : R01 HS023317
Pays : United States
Organisme : NIGMS NIH HHS
ID : U24 GM110707
Pays : United States
Organisme : NICHD NIH HHS
ID : U54 HD070725
Pays : United States
Informations de copyright
Copyright © 2018. Published by Elsevier Ltd.
Références
Vaccine. 2017 Apr 19;35(17):2272-2278
pubmed: 28162822
Vaccine. 2014 Jul 7;32(32):4097-103
pubmed: 24814550
Vaccine. 2017 May 25;35(23):3135-3142
pubmed: 28455169
Vaccine. 2010 Jul 19;28(32):5292-300
pubmed: 20566395
BMC Public Health. 2011 Jun 02;11:425
pubmed: 21635774
Vaccine. 2011 May 12;29(21):3811-7
pubmed: 21439313
Vaccine. 2016 Sep 22;34(41):4998-5004
pubmed: 27576077
Vaccine. 2015 Jun 22;33(28):3242-7
pubmed: 25889160